Chad Souvignier

Chad Souvignier is a board member at seqWell. Chad has also served on the board of directors for Calosyn Pharma, Jenrin Discovery, and Esperance Pharmaceuticals. In addition, they were the president of Aeson Therapeutics and a scientist at Optical Sensors Inc.

Chad Souvignier began their career in 1993 as a scientist at Optical Sensors Inc. Chad then became an intern at Procter & Gamble in 1999. In 2000, they started working at Guilford Pharmaceuticals as the international marketing manager. Chad was responsible for launching Gliadel Wafer, a brain tumor treatment, in Ex-US markets. Chad also established and oversaw partnerships with several regional pharmaceutical companies. In 2004, they became the president of Aeson Therapeutics. Two years later, they joined Esperance Pharmaceuticals as a member of the board of directors. In 2008, they also became a member of the board of directors for Calosyn Pharma and Jenrin Discovery.

Chad Souvignier has a MBA from the University of Arizona - Eller College of Management, a PhD in Materials Science from the University of Arizona, an MS in Polymer Science from The University of Akron, and a BS in Chemistry and Business from the University of Wisconsin-Eau Claire.